Drug Profile
Research programme: African trypanosomiasis therapies - Sanofi/DNDi
Alternative Names: Genz-644131; Neglected disease therapeutics - Sanofi/DNDi ; Sanofi 644131Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Genzyme Corporation
- Class Antiprotozoals; Small molecules
- Mechanism of Action Adenosylmethionine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in African trypanosomiasis in Switzerland
- 16 Jul 2016 No recent reports of development identified for preclinical development in African trypanosomiasis in USA
- 31 May 2009 Preclinical pharmacodynamics and pharmacokinetics data in African trypanosomiasis released by Genzyme